S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)

Acrivon Therapeutics (ACRV) News Today

$4.92
-0.06 (-1.20%)
(As of 12/29/2023 ET)
SourceHeadline
msn.com logoTravere Therapeutics, Replimune among healthcare movers
msn.com - December 5 at 2:12 PM
marketbeat.com logo
marketbeat.com - December 4 at 4:03 PM
msn.com logoAcrivon Therapeutics files for $300M mixed shelf
msn.com - December 1 at 7:08 PM
markets.businessinsider.com logoAcrivon Announces Breakthrough Device Designation For ACR-368 OncoSignature Assay
markets.businessinsider.com - November 28 at 10:10 AM
marketwatch.com logoAcrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer Assay
marketwatch.com - November 28 at 10:10 AM
markets.businessinsider.com logoAcrivon Gets FDA's Breakthrough Device Designation For ACR-368 OncoSignature Assay
markets.businessinsider.com - November 28 at 10:10 AM
marketbeat.com logo
marketbeat.com - November 13 at 9:53 AM
benzinga.com logoAcrivon Therapeutics Stock (NASDAQ:ACRV), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 11 at 7:50 AM
markets.businessinsider.com logoAnalyst Ratings for Acrivon Therapeutics
markets.businessinsider.com - November 10 at 9:00 PM
markets.businessinsider.com logoPromising Future for Acrivon Therapeutics: Buy Rating Justified by Clinical Success and Expanding Market Opportunities
markets.businessinsider.com - November 10 at 10:47 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Acrivon Therapeutics, Inc. (ACRV)
markets.businessinsider.com - November 10 at 5:46 AM
msn.com logoAcrivon Therapeutics GAAP EPS of -$0.66 beats by $0.04
msn.com - November 9 at 5:35 PM
benzinga.com logoRecap: Acrivon Therapeutics Q3 Earnings
benzinga.com - November 9 at 12:35 PM
finance.yahoo.com logoAcrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - October 16 at 12:48 PM
finance.yahoo.com logoAcrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - October 14 at 1:02 PM
markets.businessinsider.com logoAnalyst Expectations for Acrivon Therapeutics's Future
markets.businessinsider.com - October 5 at 7:05 PM
msn.com logoMaxim Group Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy Recommendation
msn.com - October 5 at 7:05 PM
marketbeat.com logo
marketbeat.com - October 5 at 9:33 AM
marketbeat.com logo
marketbeat.com - October 4 at 9:33 AM
finanznachrichten.de logoAcrivon Therapeutics, Inc: Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finanznachrichten.de - September 29 at 11:06 PM
finance.yahoo.com logoAcrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
finance.yahoo.com - September 19 at 9:06 PM
finance.yahoo.com logoAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
finance.yahoo.com - September 5 at 4:58 PM
finance.yahoo.com logoAcrivon Therapeutics to Participate in Two Investor Conferences in September
finance.yahoo.com - August 30 at 10:50 AM
msn.com logoJonesTrading Initiates Coverage of Acrivon Therapeutics (ACRV) with Buy Recommendation
msn.com - August 18 at 6:39 PM
marketbeat.com logoAcrivon Therapeutics (NASDAQ:ACRV) Earns Buy Rating from Analysts at Jonestrading
marketbeat.com - August 18 at 8:17 AM
finance.yahoo.com logoAcrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - August 17 at 4:40 PM
marketbeat.com logoFederated Hermes Inc. Sells 209,675 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
marketbeat.com - August 14 at 5:37 AM
finanznachrichten.de logoAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
finanznachrichten.de - August 11 at 6:46 PM
finance.yahoo.com logoAcrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
finance.yahoo.com - August 11 at 6:46 PM
finance.yahoo.com logoAcrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
finance.yahoo.com - July 20 at 8:09 AM
marketbeat.com logoAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Rating of "Buy" by Analysts
marketbeat.com - July 11 at 2:23 AM
finance.yahoo.com logoAcrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
finance.yahoo.com - June 22 at 8:35 PM
marketbeat.com logoAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 6.3% in May
marketbeat.com - June 19 at 1:18 AM
marketbeat.com logoAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Average Recommendation of "Buy" by Brokerages
marketbeat.com - June 16 at 4:22 AM
benzinga.com logoAcrivon Therapeutics 10% Owner Trades Company's Stock
benzinga.com - June 15 at 3:59 PM
marketbeat.com logo284,201 Shares in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Purchased by HealthCor Management L.P.
marketbeat.com - June 15 at 6:11 AM
finance.yahoo.com logoAcrivon Therapeutics to Present at the Jefferies Healthcare Conference
finance.yahoo.com - June 2 at 10:15 AM
marketbeat.com logoAcrivon Therapeutics, Inc. (NASDAQ:ACRV) Forecasted to Earn Q2 2023 Earnings of ($0.56) Per Share
marketbeat.com - May 12 at 8:52 AM
markets.businessinsider.com logoH.C. Wainwright Sticks to Their Buy Rating for Acrivon Therapeutics, Inc. (ACRV)
markets.businessinsider.com - May 10 at 9:10 AM
finance.yahoo.com logoQ1 2023 Akoya Biosciences Inc Earnings Call
finance.yahoo.com - May 9 at 2:32 PM
finanznachrichten.de logoAcrivon Therapeutics, Inc: Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
finanznachrichten.de - May 9 at 9:31 AM
finance.yahoo.com logoAcrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
finance.yahoo.com - May 9 at 9:31 AM
finance.yahoo.com logoAcrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
finance.yahoo.com - May 9 at 9:31 AM
markets.businessinsider.com logoAcrivon Therapeutics, Inc. (ACRV) Receives a Buy from BMO Capital
markets.businessinsider.com - May 9 at 4:30 AM
marketbeat.com logoAcrivon Therapeutics, Inc.'s Lock-Up Period To Expire on May 15th (NASDAQ:ACRV)
marketbeat.com - May 8 at 1:33 AM
finance.yahoo.com logoWe Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
finance.yahoo.com - May 7 at 10:45 AM
msn.com logoHC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation
msn.com - May 3 at 1:18 AM
marketbeat.com logoBank of Montreal Can Makes New Investment in Acrivon Therapeutics, Inc. (NASDAQ:ACRV)
marketbeat.com - May 2 at 4:48 AM
finance.yahoo.com logoAcrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
finance.yahoo.com - April 25 at 10:46 AM
finance.yahoo.com logoAcrivon Therapeutics to Host Virtual Investor Event on May 1, 2023
finance.yahoo.com - April 24 at 8:34 AM
Get Acrivon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.



ACRV Media Mentions By Week

ACRV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ACRV
News Sentiment

1.89

0.84

Average
Medical
News Sentiment

ACRV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ACRV Articles
This Week

1

1

ACRV Articles
Average Week

Get Acrivon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ACRV) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -